Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 20;224(11):1907–1915. doi: 10.1093/infdis/jiab243

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by Oxford University Press for the Infectious Diseases Society of America 2021.

This work is written by (a) US Government employee(s) and is in the public domain in the US.

PMC Copyright notice

Figure 1. — Antibody responses through months 9–12 after vaccination with recombinant vesicular stomatitis virus–Zaire Ebola virus envelope glycoprotein (GP) vaccine, by baseline asymptomatic malaria infection, in the immunogenicity substudy of the Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE). A, B, GP enzyme-linked immunosorbent assay (ELISA) results. C, D, Plaque reduction neutralization test (PRNT) results, including geometric mean titers (GMTs) (A, C) and seroresponse percentages (B, D). A ≥2-fold increase from baseline along with ≥200 ELISA units (EU)/mL was the definition that best differentiated vaccine from placebo recipients in the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) clinical trial. Abbreviation: CI, confidence interval.